Feasibility and effectiveness of oral cholera vaccine in an urban endemic setting in Bangladesh: a cluster randomised open-label trial
- PMID: 26164097
- DOI: 10.1016/S0140-6736(15)61140-0
Feasibility and effectiveness of oral cholera vaccine in an urban endemic setting in Bangladesh: a cluster randomised open-label trial
Abstract
Background: Cholera is endemic in Bangladesh with epidemics occurring each year. The decision to use a cheap oral killed whole-cell cholera vaccine to control the disease depends on the feasibility and effectiveness of vaccination when delivered in a public health setting. We therefore assessed the feasibility and protective effect of delivering such a vaccine through routine government services in urban Bangladesh and evaluated the benefit of adding behavioural interventions to encourage safe drinking water and hand washing to vaccination in this setting.
Methods: We did this cluster-randomised open-label trial in Dhaka, Bangladesh. We randomly assigned 90 clusters (1:1:1) to vaccination only, vaccination and behavioural change, or no intervention. The primary outcome was overall protective effectiveness, assessed as the risk of severely dehydrating cholera during 2 years after vaccination for all individuals present at time of the second dose. This study is registered with ClinicalTrials.gov, number NCT01339845.
Findings: Of 268,896 people present at baseline, we analysed 267,270: 94,675 assigned to vaccination only, 92,539 assigned to vaccination and behavioural change, and 80,056 assigned to non-intervention. Vaccine coverage was 65% in the vaccination only group and 66% in the vaccination and behavioural change group. Overall protective effectiveness was 37% (95% CI lower bound 18%; p=0·002) in the vaccination group and 45% (95% CI lower bound 24%; p=0·001) in the vaccination and behavioural change group. We recorded no vaccine-related serious adverse events.
Interpretation: Our findings provide the first indication of the effect of delivering an oral killed whole-cell cholera vaccine to poor urban populations with endemic cholera using routine government services and will help policy makers to formulate vaccination strategies to reduce the burden of severely dehydrating cholera in such populations.
Funding: Bill & Melinda Gates Foundation.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Comment in
-
Oral cholera vaccines in endemic countries.Lancet. 2015 Oct 3;386(10001):1321-1322. doi: 10.1016/S0140-6736(15)60246-X. Epub 2015 Jul 9. Lancet. 2015. PMID: 26164098 No abstract available.
-
Safe water, sanitation, hygiene, and a cholera vaccine.Lancet. 2016 Jan 2;387(10013):28. doi: 10.1016/S0140-6736(15)01294-5. Lancet. 2016. PMID: 26766343 No abstract available.
Similar articles
-
Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial.Lancet. 2009 Nov 14;374(9702):1694-702. doi: 10.1016/S0140-6736(09)61297-6. Epub 2009 Oct 8. Lancet. 2009. PMID: 19819004 Clinical Trial.
-
Efficacy of a Single-Dose, Inactivated Oral Cholera Vaccine in Bangladesh.N Engl J Med. 2016 May 5;374(18):1723-32. doi: 10.1056/NEJMoa1510330. N Engl J Med. 2016. PMID: 27144848 Clinical Trial.
-
Effectiveness of a killed whole-cell oral cholera vaccine in Bangladesh: further follow-up of a cluster-randomised trial.Lancet Infect Dis. 2021 Oct;21(10):1407-1414. doi: 10.1016/S1473-3099(20)30781-7. Epub 2021 Jun 16. Lancet Infect Dis. 2021. PMID: 34146473 Free PMC article. Clinical Trial.
-
Trials of the killed oral cholera vaccine (Shanchol) in India and Bangladesh: Lessons learned and way forward.Vaccine. 2020 Feb 29;38 Suppl 1:A127-A131. doi: 10.1016/j.vaccine.2019.06.082. Epub 2019 Jul 10. Vaccine. 2020. PMID: 31301917 Review.
-
Development of Peru-15 (CholeraGarde), a live-attenuated oral cholera vaccine: 1991-2009.Expert Rev Vaccines. 2009 Dec;8(12):1643-52. doi: 10.1586/erv.09.137. Expert Rev Vaccines. 2009. PMID: 19943759 Review.
Cited by
-
Effective community-based interventions to prevent and control infectious diseases in urban informal settlements in low- and middle-income countries: a systematic review.Syst Rev. 2024 Oct 4;13(1):253. doi: 10.1186/s13643-024-02651-9. Syst Rev. 2024. PMID: 39367477 Free PMC article.
-
Estimating time-varying cholera transmission and oral cholera vaccine effectiveness in Haiti and Cameroon, 2021-2023.medRxiv [Preprint]. 2024 Aug 16:2024.06.12.24308792. doi: 10.1101/2024.06.12.24308792. medRxiv. 2024. PMID: 39185512 Free PMC article. Preprint.
-
Do Oral Cholera Vaccine and Water, Sanitation, and Hygiene Combine to Provide Greater Protection Against Cholera? Results From a Cluster-Randomized Trial of Oral Cholera Vaccine in Kolkata, India.Open Forum Infect Dis. 2024 Jan 10;11(1):ofad701. doi: 10.1093/ofid/ofad701. eCollection 2024 Jan. Open Forum Infect Dis. 2024. PMID: 38274552 Free PMC article.
-
Oral killed cholera vaccines for preventing cholera.Cochrane Database Syst Rev. 2024 Jan 10;1(1):CD014573. doi: 10.1002/14651858.CD014573. Cochrane Database Syst Rev. 2024. PMID: 38197546 Free PMC article. Review.
-
Better Existing Water, Sanitation, and Hygiene Can Reduce the Risk of Cholera in an Endemic Setting: Results From a Prospective Cohort Study From Kolkata, India.Open Forum Infect Dis. 2023 Nov 21;10(11):ofad535. doi: 10.1093/ofid/ofad535. eCollection 2023 Nov. Open Forum Infect Dis. 2023. PMID: 38023545 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
